The idea is to try and edit genes responsible for haemophilia.
Using DNA as a medicine is a comparatively new trend in the pharma industry. The global market of gene therapy drugs is estimated to exceed USD 600 billion. Such drugs help edit flawed genes.
St. Petersburg researchers are currently developing medicines for treating such hereditary deceases as haemophilia and spinal muscular atrophy. If they succeed, Russian patients will have a better access to therapy.
According to Pavel Gershovich, head of the Biocad prospective cell research lab, there exist medicines with a similar effect, but they are very expensive. For example, the only registered medicine of this type for spinal muscular atrophy in the United States costs over 2-2.5 million dollars.
Definitely, Russia needs its own medicines as such expensive drugs are not affordable for most patients, which are quite numerous, there at least several thousands of them in Russia, says Pavel Gershovich.
Experts forecast that the gene therapy market will grow by 30% on the average annually and will exceed 4.4 billion dollars by 2023.